Stocks · News reference
Neurocrine Biosciences announced new research establishing a 6-point improvement on the EQ Visual Analogue Scale as a benchmark for clinically meaningful change in patients with tardive dyskinesia treated with INGREZZA.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Neurocrine Biosciences announced the publication of expert perspectives in the Orphanet Journal of Rare Diseases regarding the management of hyperphagia in Prader-Willi syndrome.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's disease.